Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL) entered an exclusive collaboration framework with Molteni Farmaceutici on March 3, 2026, to pursue European commercialization of AD04. The framework anticipates nearly $60 million in potential milestones and royalties, subject to a definitive agreement and AD04 progressing through clinical development.

The pact grants Molteni exclusivity to evaluate feasibility and sets terms for upfront, milestone, and tiered royalties (high single to low double digits). Adial cites genotype-driven Phase 3 design, manufacturing arrangements, a patent filing extending LOE to 2045 if granted, and simplified cheek-swab genetic screening.

Positive

• Potential aggregate royalties and milestones of nearly $60 million
• Patent filing could extend LOE from 2031 to 2045 if granted
• Manufacturing agreements secured with Thermo Fisher and Cambrex
• Genotype-driven Phase 3 design reduces trial complexity and de-risking

Negative

• Collaboration is a framework and subject to execution of a definitive agreement
• Estimated $60 million is contingent on successful clinical development and commercialization
• Patent extension is conditional on patent grant, not yet guaranteed

Key Figures

Potential royalties & milestones: Nearly $60 million Registered resale shares: 13,823,512 shares Series F exercise price: $0.31 +5 more

8 metrics

Potential royalties & milestones Nearly $60 million European AD04 collaboration framework, over time

Registered resale shares 13,823,512 shares S-3 shelf for Series F warrant shares

Series F exercise price $0.31 Exercise price for Series F warrants

Prior warrant proceeds $2.86 million Gross proceeds from Series C-1 and E warrant exercise

Potential Series F proceeds $4.29 million Estimated net proceeds if all Series F warrants exercised

Quarterly net loss $1.79 million Net loss for Q3 2025

Cash & equivalents $4.61 million Balance at September 30, 2025

Exclusivity extension 14 years (to 2045) Potential LOE extension for AD04 patent if granted

Market Reality Check

Price: $2.48 Vol: Volume 50,487 is below th...

normal vol

$2.48 Last Close

Volume Volume 50,487 is below the 20-day average of 68,828, suggesting limited pre-news positioning. normal

Technical Shares at $2.48 are trading below the 200-day MA of $8.69 and sit 91.8% under the 52-week high of $30.25.

Peers on Argus

ADIL was down 2.37% while key biotech peers showed mixed moves (e.g., ALZN up 3....

2 Up

ADIL was down 2.37% while key biotech peers showed mixed moves (e.g., ALZN up 3.08%, TNFA down 9.72%). Momentum scanner flagged other tickers (IBO, AIM) moving up, but no clear, coordinated sector reaction tied to this news.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Nasdaq compliance regained	Positive	+4.7%	Regained Nasdaq bid-price compliance while highlighting AD04 Phase 3 preparation.
Feb 23	Regulatory policy update	Positive	-4.9%	FDA policy shift could allow one pivotal trial plus confirmatory evidence for AD04.
Feb 17	Investor conference	Neutral	-5.3%	Oppenheimer conference presentation and investor meetings announcement.
Feb 4	Policy directive clinical	Positive	-25.8%	Congressional directive on alternative SUD endpoints seen as strengthening AD04 path.
Feb 3	Reverse stock split	Negative	-25.8%	1-for-25 reverse split to address Nasdaq minimum bid price requirement.

Pattern Detected

Recent history shows sharp negative reactions even to seemingly supportive regulatory or policy updates, while structurally negative events like the reverse split have also drawn selling. Market responses to news have been volatile and often diverged from the apparent tone.

Recent Company History

Over the last few months, Adial has focused on maintaining its Nasdaq listing, restructuring its capital base, and advancing AD04 toward Phase 3. A 1-for-25 reverse split and subsequent compliance regain with Nasdaq framed the listing story. Regulatory and policy developments, including FDA guidance and a Congressional directive supportive of alternative endpoints for AUD, aimed to clarify AD04’s path. Conference participation and partnering efforts set the backdrop for today’s European collaboration framework announcement.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-12-12

An effective S-3 shelf dated Dec 12, 2025 registers up to 13,823,512 shares for resale upon exercise of Series F warrants at $0.31. Adial would receive cash only if these warrants are exercised, while the large registered amount relative to prior share count creates potential dilution and stock overhang.

Market Pulse Summary

This announcement establishes an exclusive European commercialization framework for AD04 with Molten...

Analysis

This announcement establishes an exclusive European commercialization framework for AD04 with Molteni, anticipating nearly $60 million in potential milestones and royalties upon a definitive agreement. It complements prior efforts to refine AD04’s Phase 3 strategy, extend potential exclusivity to 2045, and secure manufacturing partners. Investors may watch execution of a final agreement, Phase 3 initiation, financing steps under the existing S-3, and how ADIL manages dilution and cash needs alongside this partnership.

Key Terms

phase 3, genotype, loss of exclusivity (loe), alcohol use disorder (aud), +1 more

5 terms

phase 3 medical

"AD04 advances toward pivotal Phase 3 development"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

genotype medical

"By enrolling only patients with the responsive genotype"

The genotype is an organism’s set of genes — its genetic makeup — that helps determine traits and how it responds to drugs or diseases. For investors, genotype matters because genetic differences can shape whether a therapy works, which patients are eligible, and how large or specialized a market will be; think of it like a product’s compatibility list that decides who can use it and how well it performs.

loss of exclusivity (loe) regulatory

"would extend the Loss of Exclusivity (LOE) date by an additional 14 years"

Loss of exclusivity (LOE) is when legal protections that let a company sell a product without direct copies — such as patents or regulatory exclusivity — expire, allowing competitors to offer lower-cost versions. For investors, LOE matters because it often leads to sharp drops in sales and profit margins for the original product, similar to a bestselling recipe becoming public and others selling cheaper versions, and can significantly affect a company’s revenue forecasts and valuation.

alcohol use disorder (aud) medical

"clinical endpoint for Alcohol Use Disorder (AUD)"

A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.

royalties financial

"tiered royalties (ranging from high single digits to low double digits)"

Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.

AI-generated analysis. Not financial advice.

The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 development

GLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement with Molteni Farmaceutici (“Molteni”) for a proposed exclusive partnership covering the commercialization of AD04 in Europe.

The collaboration framework, which is subject to execution of a final definitive agreement, sets forth the strategic and financial parameters of the planned partnership, covering clinical, regulatory, manufacturing, and commercial terms. Under the framework, Molteni has been granted a period of exclusivity to evaluate the feasibility of the project, conduct planning, due diligence, and a comprehensive assessment of the requirements for the successful commercial launch of AD04 across Europe.

The definitive agreement is expected to include an upfront payment, milestone payments tied to development and commercial progress, and tiered royalties (ranging from high single digits to low double digits) on European AD04 net sales, payable to Adial. The total potential aggregate value from royalties and milestones over time is estimated at nearly $60 million, assuming AD04 progresses through clinical development and is successfully introduced in the European market

This collaboration framework represents Adial’s first step toward establishing a European commercial pathway for AD04.

Molteni, established in 1892 and headquartered in Florence, Italy, is a long-established specialty pharmaceutical company with a strong presence in pain management and Substance Use Disorder (SUD) treatment. Molteni maintains integrated in-house manufacturing, research and development (R&D), regulatory, supply chain, and commercial capabilities, along with extensive distribution coverage across Europe and globally.

Cary Claiborne, President and Chief Executive Officer of Adial, commented, “This agreement represents a significant milestone for Adial and would be our first commercial partnership. Molteni brings deep expertise in SUD treatment and a well-established European infrastructure spanning regulatory, manufacturing, and commercialization. Molteni’s longstanding focus in SUD treatment and integrated European platform make them an ideal partner as we advance AD04 toward commercialization. We believe this collaboration framework validates the commercial potential of AD04 and supports our strategy to advance AD04 in both Europe and the United States.”

This partnership follows a multi-year effort to restructure, refine and optimize the AD04 clinical development program, informed by prior clinical insights. Since that time, the Company has implemented several key advancements designed to position AD04 for commercialization:

• Precision, Genotype-Driven Development: A rigorous re-analysis of clinical data identified that efficacy is largely driven by a single nucleotide polymorphism (SNP). By enrolling only patients with the responsive genotype, Adial has enabled the design of a more focused, cost-efficient clinical program with a significantly de-risked profile and a high probability of success.
• Integrated U.S. and European Regulatory Strategy: Post-hoc analysis and clinical modeling utilizing a more rigorous U.S. regulatory endpoint increases the probability of achieving the established European Medicines Agency (EMA) clinical endpoint for Alcohol Use Disorder (AUD). This refined strategy supports an integrated clinical program designed for the planned simultaneous development of AD04 for the United States, European Union, and United Kingdom markets.
• Manufacturing and Supply Chain Readiness: The Company has secured agreements with leading U.S. manufacturers, including Thermo Fisher Scientific and Cambrex, to support a secure supply chain for the production of AD04 for clinical trials and potential post-approval commercialization.
• Intellectual Property Fortification: Adial filed a new patent covering its recent clinical analysis findings. If granted, this patent would extend the Loss of Exclusivity (LOE) date by an additional 14 years, from 2031 to 2045, providing over a decade of potential commercial exclusivity post-launch.
• Simplified Genetic Screening: The prior blood draw process for genetic screening has been replaced with a modern, fast, and cost-effective cheek swab test. This improvement reduces procedural complexity and the burden on physicians and patients, supporting scalable adoption in clinical practice.
  
  

Gianluca Corbinelli, CEO of Molteni, added, “This collaboration aligns with Molteni’s strategic focus in Substance Use Disorder treatment, and we believe AD04 represents a compelling opportunity in a large area of unmet need. We are excited to enter into this exclusive framework agreement with Adial and begin building the foundation for a potential European commercialization partnership. We believe our integrated capabilities across development, manufacturing, regulatory, and commercialization position us well to support the goal of bringing this genetically targeted therapeutic option to patients in need.”

Adial is also actively engaging with potential commercial partners in the United States as it prepares to initiate its pivotal Phase 3 program in the near term.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, with no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding establishing an European commercial pathway for AD04, executing a final definitive agreement regarding the partnership, the definitive agreement including an upfront payment, milestone payments tied to development and commercial progress, and tiered royalties on European AD04 net sales, payable to Adial, the total potential aggregate value from milestones and royalties over time being estimated at nearly $60 million, AD04 progressing through clinical development and being successfully introduced in the European market, Molteni’s longstanding focus in SUD treatment and integrated European platform making them an ideal partner as the Company advances AD04 toward commercialization, the collaboration framework validating the commercial potential of AD04 and supporting the Company’s strategy to advance AD04 in both Europe and the United States, restructuring, refining and optimizing the AD04 clinical development program, positioning AD04 for commercialization, designing a more focused, cost-efficient clinical program with a significantly de-risked profile and a high probability of success, post-hoc analysis and clinical modeling utilizing a more rigorous U.S. regulatory endpoint increasing the probability of achieving the established EMA clinical endpoint for AUD, the strategy supporting an integrated clinical program designed for the planned simultaneous development of AD04 for the United States, European Union, and United Kingdom markets, agreements with leading U.S. manufacturers supporting a secure supply chain for the production of AD04 for clinical trials and potential post-approval commercialization, the new patent, if granted, extending the LOE by an additional 14 years providing over a decade of potential commercial exclusivity post-launch, the cheek swab test supporting scalable adoption in clinical practice, Molteni’s integrated capabilities across development, manufacturing, regulatory, and commercialization positioning it well to support the goal of bringing Adial’s genetically targeted therapeutic option to patients in need, initiating the Company’s pivotal Phase 3 program in the near term and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, including our ability to finalize and enter into a definitive agreement regarding the planned partnership with Molteni, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing as well as the Parties’ ability to enter into a definitive agreement. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com

FAQ

What does the March 3, 2026 ADIL collaboration with Molteni cover for AD04 in Europe?

It establishes an exclusive framework to negotiate commercialization terms for AD04 in Europe. According to the company, the framework grants Molteni exclusivity to evaluate feasibility, plan development, and negotiate upfront, milestone and tiered royalty terms ahead of a definitive agreement.

How much could Adial receive from the AD04 deal with Molteni (ADIL)?

The framework estimates nearly $60 million in potential royalties and milestones over time. According to the company, that aggregate value is contingent on AD04 advancing through clinical development and successful European commercialization.

What manufacturing and supply arrangements does ADIL report for AD04 clinical and commercial supply?

Adial has agreements with Thermo Fisher and Cambrex to support AD04 supply for trials and potential commercialization. According to the company, these arrangements aim to secure manufacturing and supply chain readiness ahead of pivotal development.

How will the ADIL AD04 clinical program be targeted using genetics?

Adial plans a genotype-driven Phase 3 by enrolling patients with a responsive SNP to improve efficacy signals. According to the company, post-hoc analysis identified a single SNP driving response, enabling a more focused, cost-efficient trial design with reduced risk.

Does the Molteni agreement mean AD04 is guaranteed to launch in Europe for ADIL shareholders?

No, the framework is conditional and not a definitive commercialization contract. According to the company, the framework requires a definitive agreement and successful clinical, regulatory and commercial milestones before launch and payments occur.